Skip to main content
Supplement ScienceSupplementScience

AREDS2 Formula Research & Evidence

·

This content is for informational purposes only and does not constitute medical advice. Statements about dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary — consult your healthcare provider before starting any supplement. Full disclaimer

Evidence Level

Strong

The AREDS2 trial (2013, JAMA) is the definitive study on nutritional supplementation for AMD. Sponsored by the NIH National Eye Institute, it enrolled 4,203 participants aged 50-85 with intermediate AMD or advanced AMD in one eye. The study confirmed that lutein/zeaxanthin was a safe and effective substitute for beta-carotene, eliminating the lung cancer risk in smokers. A 10-year follow-up (Chew et al., 2022) confirmed that the lutein/zeaxanthin formulation outperformed beta-carotene for AMD prevention.

Evidence by Condition

ConditionStudied DoseEvidence
Intermediate AMD (both eyes)Full AREDS2 formula dailyStrong
Advanced AMD in one eyeFull AREDS2 formula dailyStrong
Early AMD / preventionNot proven beneficial — AREDS2 studied intermediate-to-advanced AMDModerate

References

  1. RCTAge-Related Eye Disease Study 2 Research Group (2013). Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. DOI PubMed
  2. RCTChew EY, Clemons TE, Agrón E, et al. (2022). Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28. JAMA Ophthalmology. DOI PubMed
  3. RCTAge-Related Eye Disease Study Research Group (2001). A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation With Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss: AREDS Report No. 8. Archives of Ophthalmology. DOI PubMed